FA-BSA gated redox-triggered hollow mesoporous silica hybrid nanocapsule delivery system

Hui Chen,Yan Zhang,Xiangying Xin,Nannan Feng,Deqiao Wu,Junwei Zhang,Bing Fang,Nan Zhang
DOI: https://doi.org/10.1016/j.micromeso.2021.111033
IF: 5.876
2021-05-01
Microporous and Mesoporous Materials
Abstract:<p>In order to improve the degradation rate of silica framework and the targeted release ability of tumor drugs, this paper used a one-pot synthesis method to synthesize a redox with a silsesquioxane framework disulfide bridge and a particle size of about 150 nm. The triggered biodegradable organic-inorganic hybrid nanocapsule is a new and unique hollow mesoporous nanocapsule that is sequentially coupled with bovine serum albumin (BSA) and folic acid (FA) for the targeted release of adriamycin. As a "control gate", BSA can prevent the premature release of drugs until the BSA coating "opens the door" in response to Glutathione(GSH) to achieve drug release. FA specifically recognizes the folate receptor on the tumor surface to achieve tumor targeting. Under acidic PH and GSH, it can achieve accelerated and complete release of drugs, and effectively consume intracellular GSH, help break the redox barrier in hypoxic cells, cause oxidative stress, and effectively inhibit tumor growth.</p>
materials science, multidisciplinary,chemistry, physical,nanoscience & nanotechnology, applied
What problem does this paper attempt to address?
The problems that this paper attempts to solve are: how to increase the degradation rate of mesoporous silica nanoparticles and the targeted release ability of tumor drugs. Specifically, the researchers synthesized a nanocapsule with a special structure through a one - pot method - a redox - triggered hollow mesoporous silica hybrid nanocapsule with a particle size of about 150 nanometers, bridged by disulfide bonds on the siloxane skeleton. This nanocapsule achieves the targeted release of doxorubicin (Adriamycin) by coupling with bovine serum albumin (BSA) and folic acid (FA) in sequence. The following is a detailed interpretation of the core problems that the paper attempts to solve: 1. **Improving the degradation rate of the silica framework** The paper points out that although mesoporous silica materials have great potential in biomedical applications due to their high specific surface area and large pore size, their biodegradability is low, which may lead to the accumulation of nanodrug delivery systems in normal tissues, resulting in unpredictable side effects. Therefore, the researchers introduced disulfide bonds, enabling them to accelerate degradation under the action of glutathione (GSH), thereby increasing the biodegradability of the material. 2. **Achieving the targeted release of tumor drugs** To achieve the targeted release of drugs, the researchers designed a "control gate" mechanism. By using BSA as a "control gate", premature drug release can be prevented until the BSA coating "opens the door" to release the drug under the action of GSH. Meanwhile, folic acid (FA) can specifically recognize folate receptors on the tumor surface, thereby achieving tumor targeting. 3. **Optimizing drug release conditions** Research shows that under acidic pH and high - concentration GSH conditions, drugs can be accelerated and completely released. In addition, this nanocapsule can also effectively consume intracellular GSH, helping to break the redox barrier in hypoxic cells, trigger oxidative stress, and effectively inhibit tumor growth. ### Mathematical formula summary: - Drug loading efficiency formula: $$ \text{Loading Efficiency (\%)} = \frac{W_{\text{Loaded DOX}}}{W_{\text{Total DOX}}} \times 100\% $$ - Drug loading capacity formula: $$ \text{Loading Capacity (\%)} = \frac{W_{\text{Loaded DOX}}}{W_{\text{Loaded DOX}} + W_{\text{HMSNs@BSA - FA}}} \times 100\% $$ - Hemolysis rate formula: $$ \text{Hemolysis Rate (\%)} = \frac{A_{\text{sample}} - A_{\text{negative}}}{A_{\text{positive}} - A_{\text{negative}}} \times 100\% $$ In summary, the main objective of this paper is to develop a new type of redox - triggered hollow mesoporous silica hybrid nanocapsule to solve the problems of low degradation rate and insufficient drug targeting in traditional mesoporous silica materials in drug delivery.